FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and ...
The HCPCS system, however, underwent several changes before adoption by commercial payers, which action was eventually mandated by the Health Insurance Portability and Accountability Act (HIPAA) in ...
TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, is ...
Nationally Established Q Code Will Further Support the Use of Biovance® 3L by Physicians to Treat Wound Care Patients in Office Settings FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results